These Companies Are Capitalizing on Germany’s Cannabis Market…

During the last month, we have noticed an increase in the number of companies that are capitalizing on Germany’s cannabis industry.

By enacting legal recreational cannabis legislation, Germany could make history for the European Union (EU). We expect the development to create a domino type effect which will result in other members of the EU passing similar legislation.

Germany is the largest economy in the EU (by gross domestic product or GDP) and we are bullish on the long-term potential of its cannabis market. With a population that is greater than 83 million, Germany could be one of the largest cannabis markets in the world.

Although the recent increase in the number of Canadian Licensed Producers (LPs) that are focused on Germany is noticeable, this trend has been going on for years. Since 2020, several large-scale Canadian LPs have acquired cannabis production and processing facilities in countries that are part of the EU (especially Germany).

Today, we want to highlight some of the recent announcements from companies that are focused on the German cannabis market.

1. In late April, Aurora Cannabis Inc. (Nasdaq: ACB) (TSX: ACB) announced the expansion of its portfolio in Germany with the launch of two new cannabis flower products for patients. The company said the new products contain a high amount of tetrahydrocannabinol (THC) and will better meet the needs of its patients.
2. Last week, Village Farms International, Inc. (NASDAQ: VFF) announced the launch of cannabis products in Germany. The development represents an important milestone for the Canadian cannabis company. The launch is in partnership with IUVO Therapeutics GmbH, which is an importer, marketer and distributor of medical cannabis for the German market. According to IUVO, the company’s products should be available to German patients in the coming days.
3. Tilray Brands Inc. (Nasdaq: TLRY) (TSX: TLRY) has been highly focused on the cannabis opportunity in Germany and in the EU. By acquiring Aphria, the company became a much more prominent player in Germany and we are bullish on this market. Tilray tends to provide updates on the German market and we will continue to monitor this aspect of the business.

If you are interested in learning more about cannabis companies that are capitalizing on Germany, please send an email to support@technical420.comwith the subject “Leading German Cannabis Operators” to be added to our distribution list.

Company Relationship Disclosure

T420 is responsible for the T420 opinions provided in this disclosure except all sources or information provided by other parties were not verified or authenticated and T420 does not undertake to confirm or substantiate or be responsible for such information provided by other parties

Any Content posted regarding a Profiled Issuer is not a solicitation or recommendation to buy, sell or hold securities. We cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. All information should be independently verified. We are not responsible for errors or omissions in our publications, and any opinions expressed are subject to change, without notice. We do not, nor are we under any obligation to undertake due diligence or investigation or authenticate and verify whatsoever regarding Profiled Issuers or any Content posted in relation thereto and we do not receive any verification from the Profiled Issuer regarding the Content we disseminate. Similarly, while we endeavor to facilitate the provision of quality information, we are not responsible for any loss or damages caused or alleged to have been caused by its use nor verify or authenticate or update such information.

This article contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, state, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Top Stories